科学认识和应对造影剂肾病  

Scientific understanding and coping with contrast-induced nephropathy

作　　者：董碧蓉[1] Dong Birong(National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]国家老年疾病临床医学研究中心(四川大学华西医院)

出　　处：《中国临床保健杂志》2020年第1期27-29,共3页Chinese Journal of Clinical Healthcare

摘　　要：造影剂肾病是继低灌注性和药物性急性肾损伤后医院内获得性急性肾损伤的第三位病因,占医院内所有获得性急性肾损伤发病率的11%,死亡率的14%。由于依赖对比剂的操作不断增加,造影剂肾病逐年增多。研究表明,造影剂肾病的发病率在普通人群中约2%,高危人群中超过50%。本文分析了如何预防和治疗造影剂肾病,以及造影剂肾病的高危人群,旨在提高临床医师对造影剂肾病的认识,减少医院内获得性疾病的发生。Contrast-induced nephropathy is the third cause of hospital-acquired acute kidney injury following hypoperfusion and drug-induced acute kidney injury,accounting for 11%of all acquired acute kidney injury in hospitals,14%of the death rate.Contrast-induced nephropathy has increased year by year due to the increasing reliance on contrast agent operation.Studies have shown that the incidence of contrast-induced nephropathy is about 2%in the general population and more than 50%in high-risk population.This article analyzes how to prevent and treat contrast-induced nephropathy,as well as high-risk groups of contrast-induced nephropathy,in order to improve clinicians′understanding of contrast-induced nephropathy and reduce its incidence in hospitals.

关 键 词：造影剂肾病 医原性疾病 疾病管理 

分 类 号：R69[医药卫生—泌尿科学]